Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sinovac’s Q3 Soars; Company Announces New Vaccine Contract

publication date: Nov 16, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Sinovac Biotech Ltd. (北京科兴生物制品有限公司) announced it won a $3 million contract to supply its hepatitis A vaccine, Healive®, to the Shanghai government. In its Q3 earnings release today, Sinovac said revenues of Healive were down slightly from the year-earlier quarter, but sales of its flu vaccines absolutely soared, lifting Sinovac’s Q3 revenues to $21.2 million, an increase of 142%. Net income rose 606% to $5.2 million. More details...

Stock Symbol: (NSDQ: SVA)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...